NIH Stops Trial of COVID-19 Plasma Treatment after Researchers Found No Benefit
Click the image below to enlarge the infographic.
- The National Institutes of Health (NIH)Tuesday said it halted a trial testing convalescent plasma in patients with mild-to-moderate COVID-19 disease
- The NIH said it canceled the trial after an independent team of experts concluded that it was unlikely to be beneficial
- The independent data and safety monitoring board met Feb. 25 to review the data and determined that while the plasma treatment had no harmful effects, it was unlikely to benefit this patient population
- After the meeting, the board recommended that NIH stop enrolling new patients into the trial
- The Food and Drug Adminstration (FDA) had in August issued an emergency use authorization for convalescent plasma in August
- The plasma, which is taken from patients who have recovered from COVID-19 and developed antibodies to the virus, is infused in sick patients